Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Olivier Farchi"'
Autor:
Benjamin Chevalier, Oriane Karleskind, Arnaud Jannin, Olivier Farchi, Catherine Vermaut, Alexandre Escande, Clio Baillet, Stéphanie Espiard, Marie-Christine Vantyghem, Bruno Carnaille, Emmanuelle Leteurtre, Christine Do Cao
Publikováno v:
European Thyroid Journal, Vol 12, Iss 1, Pp 1-9 (2023)
Introduction: Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer with a bleak prognosis. Favorable outcomes are rare but help decipher molecular pathophysiology, investigate prognosis factors, and discover new therapeuti
Externí odkaz:
https://doaj.org/article/b439f355144a41caabf50eb3bbba0b91
Autor:
Anthony Turpin, Clotilde Descarpentries, Valérie Grégoire, Olivier Farchi, Alexis B Cortot, Philippe Jamme
Publikováno v:
The oncologist.
Cholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended first-line treatment is gemcitabine-based doublet, most commonly gemcitabine and cisplatin. There
Autor:
David Dudoignon, Sandrine Mansard, Olivier Farchi, Nora Kramkimel, Laurent Machet, A. Greliak, Laurent Mortier, Marion Oberlé, C. Descarpentries, Philippe Jamme
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A72-A73
Autor:
Louise Kalmuk, Clotilde Descarpentries, Celine Mascaux, Camille Munck, Zoulika Kherrouche, Eric Wasielewski, Lucie Ulmer, Olivier Farchi, Fabienne Escande, Michele Beau-Faller, Alexis B Cortot
Publikováno v:
Journal of Clinical Oncology. 40:e21014-e21014
e21014 Background: Although mutations in the kinase domain of MET are well described in papillary renal cell carcinoma, they are rare and poorly studied in lung cancer, but could constitute a new therapeutic target given the availability of potent ME
Publikováno v:
Journal of Clinical Oncology. 40:e21500-e21500
e21500 Background: Pan-negative melanomas (i.e. without MAPK kinase pathway alteration and C-kit wild type) account for 30% of melanomas (according to the AACR GENIE database). In case of immunotherapy failure, therapeutic options are limited. Oncoge
Autor:
Pauline Varlet, Jacques-Olivier Bay, Pascaline Etancelin, Christophe Ferrand, Mehdi Alizadeh, Olivier Farchi, Valérie Dubois, Ibrahim Yakoub-Agha, Virginie Renac, Laure Goursaud, Jean Bourhis, Isabelle Mollet
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (12), pp.S59-S64. ⟨10.1016/j.bulcan.2017.08.010⟩
Bulletin du Cancer, 2017, 104 (12), pp.S59-S64. ⟨10.1016/j.bulcan.2017.08.010⟩
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (12), pp.S59-S64. ⟨10.1016/j.bulcan.2017.08.010⟩
Bulletin du Cancer, 2017, 104 (12), pp.S59-S64. ⟨10.1016/j.bulcan.2017.08.010⟩
Resume L’analyse du chimerisme est une etape importante pour le suivi de l’allogreffe de cellules souches hematopoietiques. Elle permet de quantifier chez les patients allogreffes l’origine donneuse ou receveuse d’une population cellulaire ob
Autor:
Valérie, Dubois, Mehdi, Alizadeh, Jean Henri, Bourhis, Pascaline, Etancelin, Olivier, Farchi, Christophe, Ferrand, Laure, Goursaud, Isabelle, Mollet, Virginie, Renac, Pauline, Varlet, Ibrahim, Yakoub-Agha, Jacques-Olivier, Bay
Publikováno v:
Bulletin du cancer. 104(12S)
Chimerism analysis is an important step for the patient follow-up after hematopoietic stem cell transplantation. It is used to quantify the donor and the recipient part of a cell population issued from blood or bone marrow sample. In addition to hemo
Autor:
Turpin, Anthony, Descarpentries, Clotilde, Grégoire, Valérie, Farchi, Olivier, Cortot, Alexis B, Jamme, Philippe
Publikováno v:
Oncologist; Jan2023, Vol. 28 Issue 1, p80-83, 4p, 1 Color Photograph, 1 Diagram
Publikováno v:
Immunotherapy Weekly; 4/23/2024, p1252-1252, 1p
Autor:
Marsh, S. G. E.1
Publikováno v:
Tissue Antigens. Dec2014, Vol. 84 Issue 6, p609-613. 5p.